Abstract
Kappa opioid receptor (KOR) agonists have preclinical antipsychostimulant effects; however, adverse side effects have limited their therapeutic development. In this preclinical study, conducted in Sprague Dawley rats, B6-SJL mice, and non-human primates (NHPs), we evaluated the G-protein-biased analogue of salvinorin A (SalA), 16-bromo salvinorin A (16-BrSalA), for its anticocaine effects, side effects, and activation of cellular signaling pathways. 16-BrSalA dose-dependently decreased the cocaine-primed reinstatement of drug-seeking behavior in a KOR-dependent manner. It also decreased cocaine-induced hyperactivity, but had no effect on responding for cocaine on a progressive ratio schedule. Compared to SalA, 16-BrSalA had an improved side effect profile, with no significant effects in the elevated plus maze, light–dark test, forced swim test, sucrose self- administration, or novel object recognition; however, it did exhibit conditioned aversive effects. 16-BrSalA increased dopamine transporter (DAT) activity in HEK-293 cells coexpressing DAT and KOR, as well as in rat nucleus accumbens and dorsal striatal tissue. 16-BrSalA also increased the early phase activation of extracellular-signal-regulated kinases 1 and 2, as well as p38 in a KOR-dependent manner. In NHPs, 16-BrSalA caused dose-dependent increases in the neuroendocrine biomarker prolactin, similar to other KOR agonists, at doses without robust sedative effects. These findings highlight that G-protein-biased structural analogues of SalA can have improved pharmacokinetic profiles and fewer side effects while maintaining their anticocaine effects.
Document Type
Article
Publication Date
6-2023
Digital Object Identifier (DOI)
https://doi.org/10.3390/molecules28124848
Funding Information
This study was supported by grants from the Health Research Council (B.K.: 16/646, 22/331), NIH (T.E.P.: R01DA01851), and Kentucky Medical Services Foundation Chair (T.E.P.). This work was also supported by studentship awards from the Victoria University of Wellington, New Zealand (to A.E.).
Repository Citation
van de Wetering, Ross; Ewald, Amy; Welsh, Susan; Kornberger, Lindsay; Williamson, Samuel E.; McElroy, Bryan D.; Butelman, Eduardo R.; Prisinzano, Thomas E.; and Kivell, Bronwyn M., "The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors" (2023). Markey Cancer Center Faculty Publications. 399.
https://uknowledge.uky.edu/markey_facpub/399
Included in
Analytical Chemistry Commons, Medicinal Chemistry and Pharmaceutics Commons, Oncology Commons, Organic Chemistry Commons, Physical Chemistry Commons
Notes/Citation Information
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).